18:26 , Nov 30, 2018 |  BC Week In Review  |  Company News

Boehringer dropping ex-U.S. biosimilars programs

Boehringer Ingelheim GmbH (Ingelheim, Germany) said it will focus its biosimilar development and partnering activities on the U.S. market and discontinue its biosimilar programs in the rest of the world. Spokesperson Susan Holz told BioCentury...
00:02 , Nov 29, 2018 |  BC Extra  |  Company News

Boehringer dropping ex-U.S. biosimilars programs

Boehringer Ingelheim GmbH (Ingelheim, Germany) said it will focus its biosimilar development and partnering activities on the U.S. market and discontinue its biosimilar programs in the rest of the world. Spokesperson Susan Holz told BioCentury...
16:05 , Nov 16, 2018 |  BC Week In Review  |  Company News

California sues AbbVie over alleged Humira kickbacks

California Insurance Commissioner Dave Jones filed a lawsuit Sept. 18 accusing AbbVie Inc. (NYSE:ABBV) of "systematically and repeatedly" violating the Insurance Frauds Prevention Act by providing kickbacks to healthcare providers throughout California. According to the...
18:20 , Nov 9, 2018 |  BC Week In Review  |  Company News

AbbVie says global Humira market eroding faster than expected

AbbVie Inc. (NYSE:ABBV) Chairman and CEO Richard Gonzalez said the company now expects greater erosion in ex-U.S. sales of autoimmune drug Humira adalimumab by the end of next year than previously guided. During the pharma’s...
22:55 , Nov 2, 2018 |  BC Extra  |  Company News

AbbVie says global Humira market eroding faster than expected

AbbVie Inc. (NYSE:ABBV) Chairman and CEO Richard Gonzalez said the company now expects greater erosion in ex-U.S. sales of autoimmune drug Humira adalimumab by the end of next year than previously guided. During the pharma’s...
20:41 , Oct 5, 2018 |  BC Week In Review  |  Company News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...
23:34 , Oct 3, 2018 |  BC Extra  |  Politics & Policy

Phage display founders win Nobel for chemistry

The 2018 Nobel Prize for Chemistry was awarded to three scientists for their work on directed evolution of proteins and enzymes, which led to the development of human antibody-based therapeutics. The first, Humira adalimumab from...
23:52 , Oct 1, 2018 |  BC Extra  |  Company News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...
20:38 , Sep 21, 2018 |  BioCentury  |  Politics, Policy & Law

Filling the rebate void

HHS’s proposal to eliminate drug rebates should have the intended consequence of increasing transparency into drug pricing in the short term. But the long view is that value-based pricing or alternative co-pay agreements will do...
17:06 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

CHMP positive on patisiran, Symkevi, Humira and Neulasta biosimilars

EMA's CHMP recommended a number of approvals July 26, including Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Symkevi tezacaftor/ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a handful of cancer therapies and three biosimilars. The committee recommended...